Imfinzi (durvalumab) for the Treatment of Metastatic Urothelial Carcinoma (mUC)

Imfinzi ™ (durvalumab) is a monoclonal antibody (mAb) indicated for the treatment of metastatic urothelial carcinoma (mUC).
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news